Representatives from the Chinese side say they think it likely that Chinese President Xi Jinping will attend the G-20 meeting later this month. But in order to reach a trade...China Economyread more
Software engineers straight out of college often make six-figure salaries, not counting equity compensation.Technologyread more
Wall Street, though, is clamoring for a rate cut, with an 85% chance of a move in July and a 61% probability of three reductions by year's end.The Fedread more
A company spokesperson said the outage was the result of a "an internal technology issue" and was not security related.Retailread more
The flattening of the yield curve is exuding a bad omen for the stock market if history is any guide.Marketsread more
Using MIT's living wage calculator, CNBC Make It mapped out the minimum amount a single parent must earn to meet their basic needs without relying on outside help in every...Earnread more
Hong Kong Chief Executive Carrie Lam announced at a press conference on Saturday that a contentious bill to allow extraditions to mainland China has been put on hold.China Politicsread more
Stratolaunch, the world's largest airplane, which flew once, is up for sale, sources familiar told CNBC.Investing in Spaceread more
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the...ETF Edgeread more
Mired in a crisis over its best-selling 737 Max plane, Boeing could hand the spotlight over to its rival Airbus at the Paris Air Show.Airlinesread more
A new update to the Apple Watch called watchOS 6 will notify you if the environment you're in is too loud and could damage your hearing.Technologyread more
But if the market pays little attention to natural disasters, situations like North Korea's failed missile launch do tend to rattle whole swaths of stocks, Cramer said.
"I think that this news coming out of North Korea ... would certainly produce a much higher price for this stock" on Tuesday, Cramer said of Kratos Defense, a government defense contractor. "Now, the missile is in the water, but it doesn't matter. I think that there'll be another spurt in all of the defense stocks, and Kratos will figure prominently in that."
Six Flags' stock may have gotten hit after a weaker-than-expected earnings report in July, but CEO Jim Reid-Anderson told CNBC that he has since only reaffirmed his faith in the company.
"Last Friday, I spent $3 million buying the company's shares because I believe that the stock price, where it is today, doesn't reflect the true value of this company," Reid-Anderson told Cramer on Monday. "A 5.1 percent yield, Jim. That's the highest yield in the industry. And so right now, it's an opportunity."
While the CEO acknowledged that management was disappointed with the earnings miss, he maintained that revenue and profitability reached record highs in the second quarter.
He also said that in six of the last seven years, Six Flags shares declined during the third-quarter period, making this quarter the prime time to buy the stock.
"No two horrendous storms are alike. They're all terrible, and while it continues, the only thing that matters is that people are dying. Anything else is just much, much less important," the "Mad Money" host said. "But I know that many of you want to know if Harvey has any impact on investing, specifically on your portfolios, so I've got some ideas based on history."
So Cramer put together a worst-case scenario for those invested in the storm based on the havoc wreaked by Hurricane Katrina, another Category 3 storm that killed 2,000 and caused $100 billion in damage, according to the Federal Emergency Management Agency.
Then, Cramer spoke with Veeva Systems founder and CEO Peter Gassner, who spoke to the cloud company's new QualityOne product.
The cloud-based quality management program applies to new fields for Veeva that include cosmetics, chemicals, food and industrial manufacturing, Gassner said.
"We have an offering for them now, and we're just starting to get traction out there," the CEO told Cramer on Monday. "We're talking about health and human safety, absolutely, but we're also talking about quality as it refers to the brand reputation."
Gassner said the biggest draw for new QualityOne customers was their need to coordinate quality management with suppliers. The best way to reach suppliers is through a cloud-based system, and no programs exist currently that serve that kind of correspondence, Gassner said.
"We're going to serve this under-served market," Gassner said. "It reminds me of what ServiceNow did when they really started focusing on IT operations, really bringing a cloud solution ... and all of a sudden you've got a big market. That's what we're trying to do with QualityOne. There's a big, pent-up demand there, and I think we're uncovering it. "
Finally, Cramer looked into Esperion Therapeutics, a small-capitalization, development-stage biotechnology company that just issued a large secondary offering.
"When a little company with a red-hot stock does a big equity offering, that tends to be a pretty strong signal that you need to get more cautious," Cramer warned.
Amid years of wild trading, Esperion, which focuses on treatments for high cholesterol, has issued several stock offerings, usually following promising news about its drugs.
"First, you have to remember, as an early-stage biotech with no drugs on the market, no earnings, and no sales, this stock trades purely on how people feel about its longer-term prospects," Cramer explained. "The bottom line is that early-stage biotech stories are inherently risky. The last time Esperion did a secondary offering after announcing strong data, its stock ended up losing 90 percent of its value before it bottomed. I'm not saying that'll happen again. I just think you need to be careful, and while the company has definitely improved and it's farther along and we love stage 3, stocks like Esperion? Well, I've learned my lesson. I think they're too risky for me to recommend on Mad Money."
In response to CNBC's request for comment, an Esperion spokesperson emphasized the company's announcement of positive top-line results in its Phase 2 study of a treatment for inflammation associated with cardiovascular disease.
"Based on the positive reaction to this news, the company made the decision to opportunistically conduct a financing, helping to further strengthen their financial position as they progress further in to Phase 3 development and approval. As importantly, the financing provided large, long-term, institutional investors the opportunity to build substantial ownership positions in Esperion," the spokesperson wrote. "It's also important to highlight that the management team of Esperion continues to be "fully-invested" in the current and future success of the bempedoic acid franchise. We are large and long-term holders of Esperion stock and options."
In Cramer's lightning round, he flew through his take on some callers' favorite stocks:
KBR Inc.: "OK, that's a construction company. Could be an interesting play off of what's happening in Houston, but I am going to say let's hold off because it has too much energy exposure."
Corcept Therapeutics: "Oh man, the stock's up 100 percent. But, you know, look, they have the possibility of something for psychiatric disorders, therefore I'm going to tell you that I think that the company's a good spec. Because I know that there's a lot of buzz about what this company's up to."